NeuTrexin® (Trimetrexate)
Company
MedImmune Oncology
Use
Treatment for infections due to toxoplasma gondii and pneumocystis carinii in immunocompromised patients, including patients with AIDS
Features
Available as a sterile lyophilized powder
NIH Contribution
Active compound Trimetrexate used as antiparasitic agent in AIDs treatment
Approval Type
FDA
HHS Institute/Agency
NCI
Inventor(s)
C. Allegra, B. Chabner, J. Drake
Year
1994
Tech Cat
Therapeutic
![L-060-1990 L-060-1990](/sites/default/files/styles/large/public/images/showcase/29314/neutrexin-picid231-48.jpg?itok=Gg516RyJ)